Handbook of Disease Burdens and Quality of Life Measures pp 1243-1262 | Cite as
The Economic Burden of Rotavirus Diarrhea: Taiwan Perspectives
Worldwide, rotavirus is the principal cause of diarrheal illness in young children. Rotavirus infection causes significant morbidity and mortality, often inflicting emotional distress and financial burden on the family and the society.
Disease surveillance has revealed that the incidence of rotavirus infections in infants and young children is similar in both developing and developed countries. Despite so, the burden of mortality is most pronounced in the poorest countries with limited healthcare access, while morbidity is of greater significance in the developed countries. Asia’s diverse populations and economies therefore present a full spectrum of disease burden. The main drivers of rotavirus burden are direct costs (e.g., hospitalizations) and indirect costs (e.g., loss of productivity). Indirect costs are substantial in industrialized counties. The estimated annual social and medical costs due to rotavirus infections in the United States were over US $1 billion and US $264 million, respectively, demonstrating a clear emphasis of indirect over direct cost. In contrast, the estimated annual social and hospital costs for rotavirus-associated admission in Taiwan were US $13.3 million and US $10.4 million, respectively, showing the equivalence in direct and indirect cost burden.
Although few countries have evaluated its economic impact or considered the potential cost effectiveness (CE) of rotavirus universal mass vaccination (UMV), the magnitude of rotavirus disease burden is recognized. Rotavirus vaccine could markedly alleviate the ensuing disease toll on both society and the economy but to maximize its benefits, it will be important to increase its coverage.
KeywordsIndirect Cost National Health Insurance Program Taiwan National Health Insurance Total Indirect Cost Sentinel Hospital
List of Abbreviations:
Bureau of National Health Insurance
- ICD-9 CM codes
International Classification of Disease, ninth edition, Clinical Modification Code (ICD-9 CM Code)
reverse transcription-polymerase chain reaction
universal mass vaccination
World Health Organization
- Bureau of National Health Insurance. (2006). The National Health Insurance Annual Statistical Report, 2004. Accessed on 15 August 2006 by http://www.nhi.gov.tw/00english/e_index.htm.
- Clark HF, Offit PA, Ellis RW, Krah D, Shaw AR, Eiden JJ, Pichichero M, Treanor JJ. (1996). Arch Virol. 12: (Suppl)187–198.Google Scholar
- David LH. (2004). In: David LH (ed.) Control of Communicable Disease Manual. American Public Health Association, Washington, DC, pp. 224–227.Google Scholar
- Estes MK. (2001). In: Knipe DM, Howley PM (eds) Fields Virology, 4th ed. Lippincott-Raven, Philadelphia, PA, pp. 1747–1786.Google Scholar
- Kapikian AZ, Hoshino Y, Chanock RM (2001). In: Knipe DM, Howley PM (eds.) Fields Virology, 4th ed. Lippincott Williams & Wilkins, Philadelphia, PA, pp. 1787–1834.Google Scholar
- Vesikari T, Matson DO, Dennehy P, Damme PV, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB, Shinefield HR, Christie CD, Ylitalo S, Itzler RF, Coia ML, Onorato MT, Adeyi BA, Marshall GS, Gothefors L, Campens D, Karvonen A, Watt JP, O’Brien KL, DiNubile MJ, Clark HF, Boslego JW, Offit PA, Heaton PM. (2006). N Engl J Med. 354: 23–33.PubMedCrossRefGoogle Scholar
- World Health Organization. (2000). Report of the Meeting on Future Directions for Rotavirus Vaccine Research in Developing Countries. World Health Organization, Geneva, Switzerland, pp. 1–56.Google Scholar